An open-label, randomized, parallel-group, multicenter, non-inferiority trial comparing the effectiveness and safety of an immuno-guided strategy versus a viremia-guided strategy for the prevention of cytomegalovirus infection in seropositive kidney transplant recipients.

Trial Profile

An open-label, randomized, parallel-group, multicenter, non-inferiority trial comparing the effectiveness and safety of an immuno-guided strategy versus a viremia-guided strategy for the prevention of cytomegalovirus infection in seropositive kidney transplant recipients.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Valganciclovir (Primary) ; Ganciclovir
  • Indications Cytomegalovirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2017 Status changed from recruiting to discontinued.
    • 14 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top